RecruitingNCT07028489

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Sponsor

N-Power Medicine

Enrollment

130 participants

Start Date

Jun 5, 2025

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer

Summary

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting data on real-world patients with advanced non-small cell lung cancer (NSCLC) who have a specific EGFR gene mutation, to serve as a comparison group for a separate clinical trial. **You may be eligible if:** - You are 18 or older - You have been diagnosed with locally advanced or metastatic NSCLC with a specific EGFR mutation (exon 19 deletion or exon 21 L858R) - Your diagnosis was made on or after January 1, 2024 - You are in relatively good physical health (able to carry out daily activities) **You may NOT be eligible if:** - Your physical function is significantly impaired at the time of diagnosis - You have previously received treatment with osimertinib, amivantamab, or lazertinib Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.